|
| 桥接治疗对淋巴瘤患者CAR-T治疗后毒副反应的影响 |
| Effect of Bridging Therapy on Toxicities after Chimeric Antigen Receptor T-cell Therapy in Lymphoma Patients |
| 投稿时间：2025-05-27 修订日期：2025-06-23 |
| DOI： |
|
 |
| 中文关键词: 嵌合抗原受体T细胞疗法 淋巴瘤 毒副反应 细胞因子释放综合征 桥接治疗 |
| 英文关键词:Chimeric Antigen Receptor T-cell Therapy, Lymphoma, Toxicities, Cytokine Release Syndrome, Bridging Therapy |
| 基金项目:国家自然科学基金项目（面上项目，重点项目，重大项目）(No. U24A20679; No.82470237); 中山大学肿瘤防治中心高层次人才特殊支持计划 (CIRP-SYSUCC-0022） |
|
| 摘要点击次数: 28 |
| 全文下载次数: 0 |
| 中文摘要: |
| 嵌合抗原受体T细胞（CAR-T）疗法作为一种革命性的免疫疗法，近年来在血液系统恶性肿瘤的治疗中取得了显著成效，但其临床应用受到毒副反应的制约。随着CAR-T疗法应用的增多，对部分常见毒副反应的管理也趋于成熟。本文系统综述了CAR-T疗法的主要毒副反应及管理策略和桥接治疗对毒副反应的影响。通过对国内外最新临床试验及研究成果的总结，本文旨在为CAR-T疗法的临床应用提供科学依据和实践指导。 |
| 英文摘要: |
| Chimeric antigen receptor T-cell (CAR-T) therapy, as a revolutionary immunotherapy, has achieved remarkable results in the treatment of hematologic malignancies in recent years. However, its clinical application is limited by toxicities. With the increasing application of CAR-T therapy, the management of some common toxicities has also become mature. This article reviews the main types of toxicities, management strategies and the role of bridging therapy in the management of toxicities. By summarizing the latest clinical trials and research results at home and abroad, this article aims to provide scientific basis and practical guidance for the clinical application of CAR-T therapy. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |